

## News Release

### **Xantrex Q3 2007 results and investor conference call**

**VANCOUVER, B.C., October 18, 2007** – Xantrex Technology Inc. (TSX:XTX) will release its third quarter 2007 results after the Toronto Stock Exchange closes on Tuesday, October 30, 2007. To discuss the results, a conference call has been scheduled for Wednesday, October 31, 2007 at 6:00 am Pacific Time (9:00 am Eastern Time).

The conference call will include presentations by Xantrex's Chairman Mossadiq Umedaly, Chief Executive Officer John Wallace and Vice President and Chief Financial Officer Jay Biskupski. After the presentations, Xantrex will accept questions from analysts and institutional investors.

The public is invited to listen to the conference call in real time or by replay. To access the conference call by telephone, please call 416-644-3418 or 604-677-8677. Alternatively, the audio webcast of the conference call may be accessed through the investor events page on the Xantrex web site at [www.xantrex.com/invevents.asp](http://www.xantrex.com/invevents.asp). Audio replays will be available on the web shortly after the conclusion of the conference call.

#### **About Xantrex**

Xantrex Technology Inc. ([www.xantrex.com](http://www.xantrex.com)) is a world leader in the development, manufacturing and marketing of advanced power electronic products and systems for the renewable, programmable, mobile, and portable power markets. The company's products convert and control raw electrical power from any central, distributed, renewable, or backup power source into high-quality power required by electronic and electrical equipment. Headquartered in Vancouver, British Columbia, the company has facilities in Arlington, Washington; Livermore and San Diego, California; Elkhart, Indiana; Barcelona, Spain; and Reading, England. Xantrex is listed on the Toronto Stock Exchange under the ticker symbol "XTX".

Note that this news release contains forward-looking statements related to Xantrex Technology Inc. Such statements reflect the current views of Xantrex with respect to future events and are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in these forward-looking statements.

For further information, please contact:

Donna Clark

604-422-2601

[donna.clark@xantrex.com](mailto:donna.clark@xantrex.com)